Claudia PARISI, MD

@PARISImd

Medical Oncologist & PhD student | Passionate about lung cancer, genomics, investigational cancer therapeutics

Institut Gustave Roussy (IGR)

Joined January 2022

608Following

456Followers

Pinned

Claudia PARISI, MD@PARISImd · Apr 3

BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practice - Parisi - 2025 - Cancer - Wiley Online Library acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @dplanchard

2.0K

Claudia PARISI, MD@PARISImd · Jul 26

In Italy we have one of the most recognized hepatobiliary surgeon, well known for his contributions to liver surgery in the field of oncologic liver resection and minimally invasive techniques. I met him and I was very impressed from his humanity, kindness and honesty 💎

GGUIDO TORZILLI@TorzilliGuido · Jul 25

Pleased to announce the release of another scaffold sparing solution for boosting one stage removal of multiple bilobar colorectal liver metastases: SLICED LIVER HEPATECTOMY @HumanitasMilano @HUNIMED @IHPBA @AHPBA @EAHPBA @APHPBA @IASGO_1988 @SSATNews @SocSurgOnc @Aicep4

212

Claudia PARISI, MD Retweeted

Laurence Albiges@AlbigesL · Jun 3

Thanks #ASCO25 for the amazing opportunity to present some of the @GustaveRoussy works @FAndreMD @barlesi @drcmassard @BenjaminBesseMD @dplanchard @BarbaraPistill2 @EmelineColomba @JordiRemon @HollebecqueA @Ribeiro2M @MichelsJudith @derosa__lisa and many more !

3.0K

Claudia PARISI, MD@PARISImd · Jun 3

FRONT-BRAF: 1L immunotherapy +/- chemo vs. BRAF + MEK inhibitors in mNSCLC presented by my friend and colleague @DiFedericoMD a very kind-hearted, dedicated thoracic oncologist with a bright future ahead 🌟 🇮🇹 🇺🇸 #ASCO25 youtu.be/WgSUjS7xRJQ?si… via @YouTube

867

Claudia PARISI, MD Retweeted

Alessio Cortellini@ACortelliniMD · Jun 1

Pleasure to see @MarcelloTiseo at #ASCO2025 presenting the ALNEO academic study by the @GOIRC2015 group and making the whole 🇮🇹 thoracic oncogy community proud! @ASCO @ALKpositiveINT

601

Claudia PARISI, MD@PARISImd · Jun 2

I was in specialist training when we run ph1 trial with tarlatamab at @GustaveRoussy (2022). #asco2025: ph3 + results ✅ EXCELLENT news for our SCLC pts. 1st aim of our careers (within and outside clinical trials): improve pts outcomes

GGiannis Mountzios@g_mountzios · Jun 2

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC : ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001 ✅ improved QoL (dyspnea and cough) ✅ 27% vs 62% G3 TRAEs Grateful to all collaborators, @Amgen science team and above all our pts

600

Claudia PARISI, MD@PARISImd · Jun 2

Impact de la supplémentation orale en Akkermansia muciniphila dans le cancer du rein (RCC) , essai ev2101 Présenté par Dr @derosa__lisa @GustaveRoussy

PARISImd's tweet image. Impact de la supplémentation orale en Akkermansia muciniphila dans le cancer du rein (RCC) , essai ev2101
Présenté par Dr @derosa__lisa @GustaveRoussy

422

Claudia PARISI, MD@PARISImd · Jun 2

🕰️ Chronobiological mechanisms matter in ICI efficacy. First randomised clinical trial demonstrating improvement in ORR, PFS, OS in the Early Time-of-Day (ToD) arm 🧬 great effort by Francis Lévi from @ParisSaclay #ASCO2025

PARISImd's tweet image. 🕰️ Chronobiological mechanisms matter in ICI efficacy. First randomised clinical trial demonstrating improvement in ORR, PFS, OS in the Early Time-of-Day (ToD) arm 🧬 great effort by Francis Lévi from @ParisSaclay #ASCO2025

398

Claudia PARISI, MD Retweeted

Biagio Ricciuti, MD, PhD@BRicciutiMD · May 31

@DiFedericoMD presenting our collaborative study on 1st line BRAF/MEKi vs. #ICI for mNSCLC at #ASCO2025. ⬆️ OS with #ICI particularly in pts w/ PDL1 >1%, h/ tobacco use & TP53m. @ASCO @MarceloCorassa @mvnegrao @DanaFarber @MDAndersonNews @MSKCancerCenter

2.0K

Claudia PARISI, MD Retweeted

ACS Journal Cancer@JournalCancer · May 31

Stop by the #ASCO25 Poster Session to learn about targeted treatments for BRAF-mutated NSCLC🧬 📗Available in our Targeted Therapies in NSCLC supplement, this review illuminates how new treatments are improving outcomes: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert @dplanchard

1.0K

Claudia PARISI, MD Retweeted

Gustave Roussy@GustaveRoussy · May 31

🔹 Gustave Roussy at #ASCO25 🔹 Dr. Antoine Hollebecque, oncologist at @GustaveRoussy, presents a new combination of treatments for patients with colorectal #cancer in treatment failure at @ASCO. Press release ➡ ow.ly/Ye0r50W1Z0X

675

Claudia PARISI, MD Retweeted

Chul Kim@chulkimMD · May 30

BL-B01D1 (iza-bren), EGFRxHER3 ADC in driver mutation positive NSCLC outside of classical EGFR mutant NSCLC ORR in EGFR exon20ins/non classical EGFR NSCLC = 69.2% Activity also noted across other genomic alterations. #ASCO25

10.0K

Claudia PARISI, MD@PARISImd · May 30

Too excited to sleep 🤗 Welcome in Chicago #ASCO2025 @derosa__lisa @GustaveRoussy

1.0K

Claudia PARISI, MD Retweeted

Christophe Massard@drcmassard · May 28

New drugs @ASCO2025 @GustaveRoussy

9.0K

Claudia PARISI, MD Retweeted

d.planchard@dplanchard · May 20

Happy to have launched the 1st edition of ENDEAVOUR Lung cancer progamme in Madrid . A 3-year project that brings together highly talented medical oncologists with internationally renowned experts. Glad to see that France 🇫🇷 and @GustaveRoussy are well represented !

1.0K

Claudia PARISI, MD Retweeted

Università Cattolica@Unicatt · Apr 21

𝐏𝐨𝐩𝐞 𝐅𝐫𝐚𝐧𝐜𝐢𝐬, 𝐰𝐢𝐭𝐡 𝐡𝐢𝐬 𝐩𝐞𝐨𝐩𝐥𝐞 𝐮𝐧𝐭𝐢𝐥 𝐭𝐡𝐞 𝐞𝐧𝐝. Deep and profound gratitude from the family of Università Cattolica del Sacro Cuore, Istituto G. Toniolo and Policlinico A. Gemelli The statement: secondotempo.cattolicanews.it/news-pope-fran…

297

Claudia PARISI, MD Retweeted

OncoDaily@oncodaily · Apr 6

David Planchard: Thank you to ACS Journal Cancer for the opportunity to publish the review on BRAF lung cancer updates @dplanchard @JournalCancer oncodaily.com/blog/david-pla… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews

530

Claudia PARISI, MD Retweeted

Fore Biotherapeutics@ForeBiotx · Mar 31

Attending #AACR 2025? Check out our 2 posters featuring plixorafenib targeting BRAF-mutated tumors, including ctDNA results from a previously completed Phase 1/2a study and the study design from our Phase 2 FORTE basket study. Learn more: fore.bio/fore_biotherap…

111

Claudia PARISI, MD Retweeted

ACS Journal Cancer@JournalCancer · Apr 2

New supplement! 📗 Major advances in the systemic treatment of #NSCLC have been made over the past 20 years. CANCER is pleased to deliver 8 comprehensive reviews on targeted therapies for NSCLC written by leading global experts. acsjournals.onlinelibrary.wiley.com/toc/10970142/2… @OncoAlert

1.0K

Claudia PARISI, MD@PARISImd · Mar 27

What a fantastic dinner with my favourite collegues @DiFedericoMD @filippog92 from Italy and @mollylisc from @CHUK at #ELCC2025 Paris: connecting 🫁 researchers from all over the world

PARISImd's tweet image. What a fantastic dinner with my favourite collegues @DiFedericoMD @filippog92 from Italy and @mollylisc from @CHUK at #ELCC2025 Paris: connecting 🫁 researchers from all over the world

1.0K